Graziani Gina M, Angel Jonathan B
Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Division of Infectious Disease, The Ottawa Hospital, Ottawa, ON, Canada;
J Int AIDS Soc. 2015 Nov 9;18(1):20497. doi: 10.7448/IAS.18.1.20497. eCollection 2015.
The development of an effective therapeutic HIV vaccine that induces immunologic control of viral replication, thereby eliminating or reducing the need for antiretroviral therapy (ART), would be of great value. Besides the obvious challenges of developing a therapeutic vaccine that would generate effective, sustained anti-HIV immunity in infected individuals is the issue of how to best assess the efficacy of vaccine candidates.
This review discusses the various outcome measures assessed in therapeutic HIV vaccine clinical trials involving individuals receiving suppressive ART, with a particular focus on the role of analytical treatment interruption (ATI) as a way to assess the virologic control induced by an immunotherapy. This strategy is critical given that there are otherwise no readily available measures to determine the ability of a vaccine-induced immune response to effectively control HIV replication. The various outcome measures that have been used to assess vaccine efficacy in published therapeutic HIV vaccine clinical trials will also be discussed. Outcome measures have included the kinetics of viral rebound, the new viral set point and changes in the size of the viral reservoir. Clinically relevant outcomes such as the CD4 decline, the time to resume therapy or the time to meet the criterion to resume therapy, the proportion of participants who resume therapy and/or the development of clinical symptoms such as acute retroviral syndrome are also measures of vaccine efficacy.
Given the lack of consistency between therapeutic HIV vaccine trials in how efficacy is assessed, comparing vaccines has been difficult. It would, therefore, be beneficial to determine the most clinically relevant measure for use in future studies. Other recommendations for future clinical trials also include studying compartments in addition to blood and replacing ATIs with single-copy assays in situations in which the use of an ATI is not ideal.
开发一种有效的治疗性HIV疫苗,诱导对病毒复制的免疫控制,从而消除或减少对抗逆转录病毒疗法(ART)的需求,将具有巨大价值。除了开发一种能在感染个体中产生有效、持续抗HIV免疫力的治疗性疫苗面临的明显挑战外,如何最好地评估候选疫苗的疗效也是一个问题。
本综述讨论了在接受抑制性ART的个体参与的治疗性HIV疫苗临床试验中评估的各种结果指标,特别关注分析性治疗中断(ATI)作为评估免疫疗法诱导的病毒学控制的一种方式的作用。鉴于否则没有现成的措施来确定疫苗诱导的免疫反应有效控制HIV复制的能力,这种策略至关重要。还将讨论在已发表的治疗性HIV疫苗临床试验中用于评估疫苗疗效的各种结果指标。结果指标包括病毒反弹的动力学、新的病毒载量设定点和病毒库大小的变化。临床相关结果,如CD4下降、恢复治疗的时间或达到恢复治疗标准的时间、恢复治疗的参与者比例和/或急性逆转录病毒综合征等临床症状的出现,也是疫苗疗效的指标。
鉴于治疗性HIV疫苗试验在疗效评估方法上缺乏一致性,比较疫苗一直很困难。因此,确定未来研究中最具临床相关性的指标将是有益的。对未来临床试验的其他建议还包括除血液外研究其他区室,以及在使用ATI不理想的情况下用单拷贝检测取代ATI。